Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A targeted radioligand therapy is showing lasting promise for men with recurring prostate cancer. Extended follow-up from the phase 2 LUNAR trial found that adding 177Lu-PNT2002 before stereotactic body radiotherapy (SBRT) more than doubled progression-free survival (17.6 vs. 7.4 months) and delayed the need for hormone therapy. Researchers believe the combo may be tackling cancer cells too small to detect on imaging.
A targeted radioligand therapy is showing lasting promise for men with recurring prostate cancer. Extended follow-up data from the phase 2 LUNAR trial reveal that adding two cycles of 177Lu-PNT2002 before stereotactic body radiotherapy (SBRT) significantly improved multiple survival outcomes in patients with oligorecurrent hormone-sensitive prostate cancer (orHSPC) — those with a limited number of detectable metastatic lesions.
The trial enrolled 92 patients who were randomly assigned to receive 177Lu-PNT2002 followed by SBRT or SBRT alone. At a median follow-up of nearly 32 months, the combination arm showed meaningful gains across several key endpoints, suggesting the therapy may be targeting microscopic disease beyond what imaging can detect.
By the Numbers:
Why it matters: These findings suggest that combining radioligand therapy with radiation could meaningfully delay disease progression and reduce the need for hormone therapy — a significant quality-of-life win for patients. While exploratory, the results are compelling enough to warrant confirmatory trials.
